- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07940816
Exploring the Efficacy and Mechanism of Accelerated High-Definition Transcranial Direct Current Stimulation (HD-tDCS) in the Treatment of Obsessive-compulsive Disorder
Exploring the Efficacy and Mechanism of Accelerated High-Definition Transcranial Direct Current Stimulation (HD-tDCS) in the Treatment of Obsessive-compulsive Disorder: A Randomized Controlled Trial
This study will evaluate the therapeutic effects of accelerated high-definition transcranial direct current stimulation (HD-tDCS) as adjunct to pharmacotherapy in obsessive-compulsive disorder (OCD) patients, and the underlying neural mechanism by EEG, MRI, TMS-EEG and cognitive tasks.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to evaluate the clinical efficacy of accelerated high-definition transcranial direct current stimulation (HD-tDCS) targeting the orbitofrontal cortex (OFC) as an adjunct to pharmacotherapy in patients with obsessive-compulsive disorder (OCD), and to investigate its underlying neural mechanisms. Sixty patients with OCD receiving stable pharmacotherapy will be randomized to receive either active or sham HD-tDCS. Stimulation will be administered four times daily for five consecutive days, followed by a two-day break and another five consecutive days of treatment, for a total of 40 sessions. Before each stimulation session, symptom provocation will be conducted by a research assistant who has completed standardized training.
Symptom severity will be assessed at baseline and upon completion of the HD-tDCS intervention. Assessments conducted throughout the study will include the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), the Clinical Global Impression (CGI) scale, the Obsessive-Compulsive Inventory-Revised (OCI-R), the Beck Depression Inventory-II (BDI-II), the Beck Anxiety Inventory (BAI), the Childhood Trauma Questionnaire (CTQ), a side-effect questionnaire, and other study-specified measures. A trained investigator will administer clinician-rated measures and oversee the completion of self-report questionnaires. Participants will also undergo magnetic resonance imaging (MRI), electroencephalography (EEG), and transcranial magnetic stimulation combined with EEG (TMS-EEG).
The Iowa Gambling Task will be administered at baseline, upon completion of the HD-tDCS intervention, and at the one-month follow-up after intervention completion to assess decision-making performance. The probabilistic reversal learning task will be administered at baseline, after the first HD-tDCS session, upon completion of the intervention, and at the one-month follow-up to assess reversal learning and cognitive flexibility under probabilistic uncertainty.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Zhen Wang
- Phone Number: +8618017311286
- Email: wangzhen@smhc.org.cn
Study Locations
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China
- Shanghai Mental Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18-50 years, of Han Chinese ethnicity, and right-handed.
- Meet the diagnostic criteria for obsessive-compulsive disorder (OCD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
- Have a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score ≥16.
- Have received at least one selective serotonin reuptake inhibitor (SSRI) at an adequate dose for an adequate duration. If currently taking medication, the dose must have been stable for at least eight weeks, and the medication type and dose must remain unchanged throughout the study.
- Have completed junior high school education or above.
- Provide informed consent.
Exclusion Criteria:
- Meet DSM-5 diagnostic criteria for a psychiatric disorder other than OCD, as assessed using the Structured Clinical Interview for DSM-5 (SCID-5).
- Have obsessive-compulsive symptoms severe enough to prevent completion of the required assessments and examinations.
- Have received electroconvulsive therapy (ECT), including modified ECT, within the past six months, or any other form of neuromodulation within the past two months.
- Have a serious medical condition or any medical condition that may precipitate seizures or increased intracranial pressure, including cardiovascular or respiratory diseases.
- Have a history of neurological disorders (e.g., epilepsy or stroke), traumatic brain injury, or brain surgery.
- Have implanted medical devices or materials, such as intracranial stents, cardiac pacemakers, coronary stents, or cochlear implants.
- Be at high risk of suicide.
- Be pregnant or planning to become pregnant in the near future.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: active HD-tDCS
Active cathodal high-definition transcranial direct current stimulation (HD-tDCS) targeting the right orbitofrontal cortex (OFC) will be administered four times daily at two-hour intervals for five consecutive days, followed by a two-day break and another five consecutive days of treatment, for a total of 40 sessions. Before each stimulation session, symptom provocation will be conducted by a research assistant who has completed standardized training. |
The HD-tDCS device will deliver a direct current of 2 mA for 20 minutes per session. The cathode will be positioned at Fp2 to target the right orbitofrontal cortex (OFC), with four return anodes placed at Fpz, AFz, AF4, and AF8, according to the international 10-10 EEG electrode placement system. |
|
Sham Comparator: sham HD-tDCS
Sham high-definition transcranial direct current stimulation (HD-tDCS) targeting the right orbitofrontal cortex (OFC) will be administered four times daily at two-hour intervals for five consecutive days, followed by a two-day break and another five consecutive days of treatment, for a total of 40 sessions. Before each stimulation session, symptom provocation will be conducted by a research assistant who has completed standardized training. |
In the sham stimulation group, the current will be gradually ramped up to 2 mA over approximately 30 seconds at the beginning of each session and ramped down to 0 mA over approximately 30 seconds at the end of each session. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Symptom improvement assessed by the Yale-Brown Obsessive Compulsive Scale(Y-BOCS)
Time Frame: About 6 weeks
|
The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is a semi-structured, clinician-rated instrument used to assess the severity of obsessive-compulsive symptoms. It comprises 10 items: five assessing obsessions and five assessing compulsions. Each item is rated on a five-point scale from 0 to 4, yielding a total score ranging from 0 to 40, with higher scores indicating greater symptom severity. Treatment response is defined as a reduction of at least 35% in the Y-BOCS total score from baseline to the end of the HD-tDCS intervention. |
About 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Beck Depression Inventory-II (BDI-II)
Time Frame: About 6 weeks
|
It is a 21-item self-report measure scored on a 4-point Likert-type scale to summarize recent symptoms of depression.The higher the score, the higher the level of depression. |
About 6 weeks
|
|
The Beck Anxiety Inventory (BAI)
Time Frame: About 6 weeks
|
It is a 21-item self-report inventory that is used for measuring the severity of anxiety.The higher the score, the higher the level of anxiety. |
About 6 weeks
|
|
Side-effect questionnaire
Time Frame: About 6 weeks
|
It consists of ten commonly-reported side effects as well as an "other" category that allows participants to describe experiences/sensations not otherwise covered to rate the intensity of side effects. |
About 6 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20240XJQ03DCS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.